Q-omics provides the consensus-scored ZNF208 profile across patient tissues and cancer cell-line models. ZNF208 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZNF208 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, ZNF208 RNA expression shows 16,078 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KICH, and THYM as cancer lineages where ZNF208 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF208 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF208 survival associations across molecular data types. ZNF208 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF208 RNA expression–survival associations across cancer types. High ZNF208 expression shows unfavorable associations in BLCA, but favorable associations in MESO, UVM, LUAD, THCA and UCS. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZNF208 RNA expression.
This table summarizes ZNF208 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF208. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF208 shows lower tumor expression in KICH, LUSC, KIRC, UCEC, BRCA and COAD. The KICH box plot shows higher ZNF208 RNA expression in normal versus tumor tissue (log2 FC = −1.013, t-test p < 0.001).
This table shows molecular features associated with ZNF208 in patient tissues and cancer cell lines. In patient samples, ZNF208 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF208 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
